{
  "url": "https://finance.yahoo.com/news/could-tilray-tlry-gain-edge-101700382.html",
  "authorsByline": "Simply Wall St",
  "articleId": "73c07b1c4dd244f791611691f5fbfd66",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/fd5474a7eee0c5f442903b68fe63249b",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-29T10:17:00+00:00",
  "addDate": "2025-08-29T10:47:12.147759+00:00",
  "refreshDate": "2025-08-29T10:47:12.147761+00:00",
  "score": 1.0,
  "title": "Could Tilray (TLRY) Gain an Edge in Europe Through Its New German Medical Cannabis Launch?",
  "description": "Tilray Medical recently announced the launch of three new EU-GMP certified medical cannabis strains for patients and pharmacies across Germany, including Good Supply Cannabisbl\u00fcten THC 22 IIM, THC 25 MMK, and THC 18 LLD, available in 15 g and 500 g formats. This move highlights Tilray's growing focus on tailored European medical offerings and underscores the brand\u2019s expanding role in the German medical cannabis market. We'll examine how Tilray\u2019s introduction of EU-GMP cannabis strains in...",
  "content": "\u2022 Tilray Medical recently announced the launch of three new EU-GMP certified medical cannabis strains for patients and pharmacies across Germany, including Good Supply Cannabisbl\u00fcten THC 22 IIM, THC 25 MMK, and THC 18 LLD, available in 15 g and 500 g formats.\n\u2022 This move highlights Tilray's growing focus on tailored European medical offerings and underscores the brand\u2019s expanding role in the German medical cannabis market.\n\u2022 We'll examine how Tilray\u2019s introduction of EU-GMP cannabis strains in Germany could reinforce the company's international growth narrative.\n\nOutshine the giants: these 22 early-stage AI stocks could fund your retirement.\n\nFor investors considering Tilray Brands, the key story hinges on whether international expansion, led by new launches like the recent Germany-focused medical cannabis strains, can meaningfully offset persistent losses and market headwinds. While these launches reinforce Tilray\u2019s presence in higher-margin markets, they do not fundamentally change the immediate challenges, particularly ongoing unprofitability and constraints in core North American revenues, which remain the most important catalyst and biggest risk, respectively, for the stock right now.\n\nA closely related development is Tilray's July 2025 impairment of US$1.4 billion in intangible assets, which underscores the pressure the company faces to achieve profitable growth and improve cash flow. Both the Germany product launch and major asset write-down highlight management's emphasis on international market opportunities and balancing the pursuit of scale with financial discipline.\n\nHowever, investors should watch closely for signs of increased regulatory risk in key European markets, as...\n\nRead the full narrative on Tilray Brands (it's free!)\n\nTilray Brands' narrative projects $940.4 million in revenue and $193.4 million in earnings by 2028. This requires 4.6% yearly revenue growth and a $2.4 billion earnings increase from current earnings of -$2.2 billion.\n\nUncover how Tilray Brands' forecasts yield a $0.983 fair value, a 33% downside to its current price.\n\nEighteen estimates from the Simply Wall St Community set Tilray's fair value anywhere from US$0.98 to US$44.45 per share. While many see potential in Tilray\u2019s international growth, ongoing net losses and cash burn keep profitability questions front of mind for shareholders seeking diverse opinions.\n\nExplore 18 other fair value estimates on Tilray Brands - why the stock might be a potential multi-bagger!",
  "medium": "Article",
  "links": [
    "https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global?utm_medium=finance_user&utm_campaign=intro&utm_source=yahoo&blueprint=4024791",
    "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4024791",
    "https://simplywall.st/company/id/28c308f5-2303-4a31-934e-094ef649c68d?utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo&amp;blueprint=4024791",
    "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/9jtssl54-expanding-european-cannabis-markets-will-unlock-global-wellness-potential-myqz?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4024791"
  ],
  "labels": [
    {
      "name": "Non-news"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Tilray Brands",
      "weight": 0.113297135
    },
    {
      "name": "Tilray",
      "weight": 0.10024657
    },
    {
      "name": "Tilray Medical",
      "weight": 0.098370045
    },
    {
      "name": "international market opportunities",
      "weight": 0.085796915
    },
    {
      "name": "key European markets",
      "weight": 0.0816304
    },
    {
      "name": "tailored European medical offerings",
      "weight": 0.07575657
    },
    {
      "name": "new launches",
      "weight": 0.07419575
    },
    {
      "name": "Tilray\u2019s international growth",
      "weight": 0.06872805
    },
    {
      "name": "profitable growth",
      "weight": 0.06837684
    },
    {
      "name": "international expansion",
      "weight": 0.0679451
    }
  ],
  "topics": [
    {
      "name": "Cannabis"
    },
    {
      "name": "Social Issues"
    }
  ],
  "categories": [
    {
      "name": "Health"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.97265625
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.90771484375
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.88427734375
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.8173828125
    },
    {
      "name": "/Health/Pharmacy/Drugs & Medications",
      "score": 0.60693359375
    },
    {
      "name": "/Sensitive Subjects/Recreational Drugs",
      "score": 0.5048828125
    },
    {
      "name": "/News/Health News",
      "score": 0.337646484375
    }
  ],
  "sentiment": {
    "positive": 0.7160271,
    "negative": 0.040237993,
    "neutral": 0.24373494
  },
  "summary": "Tilray Medical has launched three new EU-GMP certified medical cannabis strains in Germany, including Good Supply Cannabisbl\u00fcten THC 22 IIM, THC 25 MMK, and THC 18 LLD. This move reflects Tilray's growing focus on tailored European medical offerings. However, challenges remain, particularly ongoing unprofitability and constraints in core North American revenues. The company's July 2025 impairment of US$1.4 billion in intangible assets underscores the pressure faced by Tilray to achieve profitable growth and improve cash flow. Despite these launches, investors should watch closely for signs of increased regulatory risk in key European markets.",
  "shortSummary": "Tilray Medical launched three EU-GMP cannabis strains in Germany, emphasizing its focus on international expansion despite ongoing losses and market headwinds.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "33c5c4f8a9d2402ebbf490a12a0490b8",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands/9jtssl54-expanding-european-cannabis-markets-will-unlock-global-wellness-potential-myqz?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4024791",
      "text": "Last Update26 Aug 25Fair value Increased 5.99%\nTilray Brands\u2019 consensus price target has increased to $0.983 as analysts cite improved U.S. political momentum toward cannabis rescheduling and Tilray\u2019s strong positioning to benefit from expanding market opportunities.\nAnalyst Commentary\n- Positive political developments, with momentum towards rescheduling marijuana from Schedule I to Schedule III in the U.S., indicating a potential shift in federal cannabis policy.\n- Increased potential for broader market access in the U.S. cannabis sector as a result of evolving legal landscape.\n- Recognition of Tilray's strong brand presence, scale, and infrastructure positions it well to capture anticipated market opportunities.\n- Confidence in the company\u2019s balance sheet to support growth as regulatory doors open.\n- Perception that current developments represent meaningful progress, though not full federal legalization, creating new avenues for growth.\nWhat's in the News\n- Tilray Brands continues expanding its hemp-derived Delta-9 THC beverage portfolio, launching new 10mg product extensions and variety packs from Fizzy Jane's and Happy Flower across multiple U.S. states, while introducing a summer collection of cannabis products in Canada, including new beverages, pre-rolls, vapes, and infused edibles (Product Announcements, 2025-06-23 & 2025-08-12).\n- Tilray Medical published a scientific study comparing the bioavailability of different THC:CBD formulations, reinforcing its leadership in EU-GMP medical cannabis and ongoing commitment to supporting clinical research globally (Product Announcement, 2025-06-26).\n- The company reported a significant impairment charge of $1.4 billion tied to intangible assets and goodwill for Q4 2025, but CEO Irwin Simon stated that Tilray remains focused on future M&A opportunities, leveraging its balance sheet strength and free cash flow (Impairment/Write Offs and Seeking Acquisitions/Investments, 2025-07-28).\n- Tilray shareholders approved a reverse stock split (ratio between 1-for-10 and 1-for-20) to maintain Nasdaq listing requirements, but the company has paused implementation while evaluating timing and market conditions; meanwhile, Tilray was recently dropped from the S&P/TSX Capped Composite, Completion, and Composite Indexes (Delistings/Index Changes, 2025-06-07/-14/-17 & Bylaws Change, 2025-06-10).\n- U.S. regulatory momentum continues with the House approving an amendment allowing VA physicians to recommend medical cannabis and President Trump reportedly considering rescheduling marijuana, which, if enacted, could benefit public cannabis companies including Tilray (Marijuana Herald, 2025-06-25; Wall Street Journal, 2025-08-10).\nValuation Changes\nSummary of Valuation Changes for Tilray Brands\n- The Consensus Analyst Price Target has risen from $0.928 to $0.983.\n- The Net Profit Margin for Tilray Brands has significantly risen from 20.56% to 23.22%.\n- The Future P/E for Tilray Brands has fallen from 7.78x to 7.31x.\nKey Takeaways\n- Expansion in Europe and category diversification are driving strong growth, margin improvements, and long-term revenue potential as global cannabis markets develop.\n- Operational efficiencies and a solid financial position support continued cost optimization, strategic acquisitions, and international market entry for ongoing earnings growth.\n- Persistent regulatory hurdles, market pressures, and industry headwinds continue to constrain Tilray's revenue growth, profitability, and exposure to solvency and dilution risks.\nCatalysts\nAbout Tilray Brands- A lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally.\n- Tilray's international cannabis business is achieving rapid organic growth, with European cannabis revenue up 112% YoY (excluding Australia) and significant share gains in Germany due to regulatory tailwinds, broader medical adoption, and expanding legalization-supporting a long runway for top-line revenue acceleration as global cannabis markets open.\n- Sustained innovation and consumer focus in wellness, energy drinks, non-alcoholic beverages, and hemp-based foods positions Tilray to capture the surge in demand for plant-based, functional, and health-oriented products, which should drive diversified, higher-margin revenues and gross margin expansion.\n- Operational scale from strategic acquisitions (craft beer/spirits) and production footprint consolidation (now 90% in-house) is enabling continued cost optimization, SKU rationalization, and manufacturing efficiency, translating into stronger gross/net margins and improved EBITDA in upcoming periods.\n- Ongoing consolidation and stabilization in Canada's cannabis sector and a shift toward higher-margin SKUs (e.g., premium flower, beverages, edibles) are reducing price compression and illicit market share, while regulatory reforms (potential for broader retail/access, excise tax changes) offer future revenue and profitability upside.\n- Tilray's robust balance sheet, substantial cash reserves, and ongoing debt reduction afford flexibility to pursue geographic expansion, new international market entries in Europe/Middle East/Asia, and opportunistic acquisitions-enhancing long-term earnings growth and financial resilience.\nTilray Brands Future Earnings and Revenue Growth\nAssumptions\nHow have these above catalysts been quantified?- Analysts are assuming Tilray Brands's revenue will grow by 4.6% annually over the next 3 years.\n- Analysts are not forecasting that Tilray Brands will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Tilray Brands's profit margin will increase from -266.3% to the average CA Pharmaceuticals industry of 20.6% in 3 years.\n- If Tilray Brands's profit margin were to converge on the industry average, you could expect earnings to reach $193.4 million (and earnings per share of $0.14) by about August 2028, up from $-2.2 billion today.\n- In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 7.8x on those 2028 earnings, up from -0.3x today. This future PE is lower than the current PE for the CA Pharmaceuticals industry at 18.1x.\n- Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.\n- To value all of this in today's terms, we will use a discount rate of 6.45%, as per the Simply Wall St company report.\nTilray Brands Future Earnings Per Share Growth\nRisks\nWhat could happen that would invalidate this narrative?- Persistently slow and uncertain progress on U.S. cannabis legalization continues to limit Tilray's addressable market, with management citing that \"U.S. regulatory changes have not advanced the way we'd hoped,\" which has suppressed share price, led to multi-billion dollar impairment charges, and risks continued stagnation in revenue and market cap.\n- Ongoing price compression, illicit market competition, and heavy excise tax burdens in the Canadian cannabis market have significantly impacted revenues-management noted price compression cost over $250 million in five years-potentially limiting future revenue growth and constraining margins.\n- Softness and overall decline in industry-wide craft beer demand, combined with \"SKU rationalization,\" missed distribution resets, and adverse weather, resulted in weaker-than-expected beverage revenues; persistent headwinds or further category contraction will negatively impact Tilray's diversified revenue and gross margin.\n- Long-term lack of operating profitability is evidenced by continued net losses (a net loss of $2.2 billion in FY 2025, with $31 million in cash losses from operations) and negative free cash flow (negative $114 million FY 2025), highlighting challenges in achieving structural cost efficiency and sustainable earnings, and heightening dilution or solvency risk.\n- Increased regulatory risk in international core markets, such as potential restrictive legislation in Germany (e.g., limiting telemedicine or mail-order medical cannabis), can disrupt access, pricing, or demand and limit the scalability of high-margin international revenues that management is relying on for future growth.\nValuation\nHow have all the factors above been brought together to estimate a fair value?- The analysts have a consensus price target of $0.928 for Tilray Brands based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $1.5, and the most bearish reporting a price target of just $0.6.\n- In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $940.4 million, earnings will come to $193.4 million, and it would be trading on a PE ratio of 7.8x, assuming you use a discount rate of 6.4%.\n- Given the current share price of $0.65, the analyst price target of $0.93 is 29.9% higher.\n- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.\nHow well do narratives help inform your perspective?\nDisclaimer\nAnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material."
    },
    {
      "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-tlry/tilray-brands?utm_medium=finance_user&utm_campaign=integrated-pitch&utm_source=yahoo&blueprint=4024791",
      "text": "Dashboard\nPortfolios\nWatchlist\nCommunity\nDiscover\nScreener\nNarratives\nYour Valuation\nLoading...\nCommunity\n/\nUnited States\n/\nPharmaceuticals & Biotech\n/\nTilray Brands\nCreate a narrative\nTilray Brands Community\nNasdaqGS:TLRY Community\n3\nNarratives\nwritten by author\n0\nComments\non narratives written by author\n157\nFair Values set\non narratives written by author\nCommunity Investing Ideas\nTilray Brands\nPopular\nUndervalued\nOvervalued\nTilray Brands\nAN\nAnalystLowTarget\nConsensus Narrative from 9 Analysts\nFragmented Legalization And Oversupply Will Hamper International Scaling\nKey Takeaways Regulatory hurdles, shifting consumer trends, and integration issues are likely to limit Tilray's revenue growth and compress margins across international markets and core business lines. Dependence on U.S. legalization, oversupply risks, and elevated operating costs threaten the company's long-term growth prospects and earnings stability.\nView narrative\nUS$0.60\nFV\n145.0% overvalued\nintrinsic discount\n4.09%\nRevenue growth p.a.\nSet Fair Value\n0\nusers have liked this narrative\n0\nusers have commented on this narrative\n0\nusers have followed this narrative\nNew\nnarrative\nTilray Brands\nAN\nAnalystConsensusTarget\nConsensus Narrative from 9 Analysts\nExpanding European Cannabis Markets Will Unlock Global Wellness Potential\nKey Takeaways Expansion in Europe and category diversification are driving strong growth, margin improvements, and long-term revenue potential as global cannabis markets develop. Operational efficiencies and a solid financial position support continued cost optimization, strategic acquisitions, and international market entry for ongoing earnings growth.\nView narrative\nUS$0.98\nFV\n49.5% overvalued\nintrinsic discount\n4.61%\nRevenue growth p.a.\nSet Fair Value\n0\nusers have liked this narrative\n0\nusers have commented on this narrative\n76\nusers have followed this narrative\nUpdated\nnarrative\nTilray Brands\nAN\nAnalystHighTarget\nConsensus Narrative from 9 Analysts\nSecular Legalization And Wellness Trends Will Transform EU Cannabis Industry\nKey Takeaways Tilray is set to dominate European medical cannabis through unique assets, distribution, and rapid market expansion, driving sustained revenue and margin growth. Broad product diversification and M&A agility position Tilray to capture new health, wellness, and beverage opportunities as global cannabis adoption increases.\nView narrative\nUS$1.50\nFV\n2.0% undervalued\nintrinsic discount\n5.21%\nRevenue growth p.a.\nSet Fair Value\n0\nusers have liked this narrative\n0\nusers have commented on this narrative\n0\nusers have followed this narrative\n9 days ago\nauthor updated this narrative\nYour Valuation for\nTLRY\nTLRY\nTilray Brands\nYour Fair Value\nUS$\nCurrent Price\nUS$1.47\n16.9% undervalued\nintrinsic discount\nGrowth estimate over\nAnnual revenue growth rate\n5 Years\ntime period\n%/yr\nDecrease\nIncrease\nPast\nFuture\n-2b\n1b\n2015\n2018\n2021\n2024\n2025\n2027\n2030\nRevenue US$1.0b\nEarnings US$151.9m\nAdvanced\nSet Fair Value"
    },
    {
      "url": "https://simplywall.st/company/id/28c308f5-2303-4a31-934e-094ef649c68d?utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo&amp;blueprint=4024791",
      "text": "Tilray Brands (TLRY) Stock Overview\nA lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 2/6 |\n| Future Growth | 0/6 |\n| Past Performance | 0/6 |\n| Financial Health | 5/6 |\n| Dividends | 0/6 |\nTLRY Community Fair Values\nSee what 148 others think this stock is worth. Follow their fair value or set your own to get alerts.\nTilray Brands, Inc. Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | US$1.47 |\n| 52 Week High | US$1.88 |\n| 52 Week Low | US$0.35 |\n| Beta | 1.95 |\n| 1 Month Change | 154.81% |\n| 3 Month Change | 245.31% |\n| 1 Year Change | -13.53% |\n| 3 Year Change | -58.94% |\n| 5 Year Change | n/a |\n| Change since IPO | -90.87% |\nRecent News & Updates\nTilray Brands Should Be Sold\nAug 20Tilray Brands, Inc. (NASDAQ:TLRY) Surges 66% Yet Its Low P/S Is No Reason For Excitement\nAug 18Recent updates\nTilray Brands Should Be Sold\nAug 20Tilray Brands, Inc. (NASDAQ:TLRY) Surges 66% Yet Its Low P/S Is No Reason For Excitement\nAug 18Tilray Brands, Inc. (NASDAQ:TLRY) Shares Fly 35% But Investors Aren't Buying For Growth\nJul 04Integrated Operations Will Extend European And US THC Beverage Markets\nStrategic initiatives focusing on margin improvements and global expansion efforts could significantly boost profitability and revenue growth.Tilray Brands Could Bounce Big\nApr 28Tilray: Q3 Earnings Could Be The Inflection Point It Needs\nApr 09Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 28% Price Drop\nMar 26Tilray Short Interest Surges Again\nMar 13Tilray: Improved Balance Sheet And Reasonable Valuation (Rating Upgrade)\nFeb 17Investors Don't See Light At End Of Tilray Brands, Inc.'s (NASDAQ:TLRY) Tunnel And Push Stock Down 27%\nFeb 07Tilray: Back To Square One (Rating Downgrade)\nJan 14Tilray: FQ2 Results Unlikely To Impress Below The Top Line\nJan 08US Delta-9 THC Markets And German Medical Cannabis Synergize Tilray's Potential\nDec 27Tilray Brands May Bounce\nDec 15Here's Why Shareholders May Want To Be Cautious With Increasing Tilray Brands, Inc.'s (NASDAQ:TLRY) CEO Pay Packet\nDec 13Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 26% Price Drop\nDec 05Tilray Brands Is Still Priced Too High\nNov 03Tilray: Another Weed In The Garden\nOct 15Tilray Q1 Preview: Germany Could Drive Earnings Surprise\nOct 08Look For Tilray To Keep Declining\nSep 08Tilray Brands (NASDAQ:TLRY) Is Making Moderate Use Of Debt\nSep 05Tilray Brands, Inc. (NASDAQ:TLRY) Shares Could Be 47% Below Their Intrinsic Value Estimate\nJul 31Tilray Shows Some Nice Improvement In Q4\nJul 30Tilray Should Be Cut From Your Portfolio\nJul 14Why Bears Think Tilray Brands Will Continue To Dip\nMay 29Shareholder Returns\n| TLRY | US Pharmaceuticals | US Market | |\n|---|---|---|---|\n| 7D | 32.4% | -0.2% | 2.3% |\n| 1Y | -13.5% | -13.3% | 17.2% |\nReturn vs Industry: TLRY matched the US Pharmaceuticals industry which returned -13.3% over the past year.\nReturn vs Market: TLRY underperformed the US Market which returned 17.2% over the past year.\nPrice Volatility\n| TLRY volatility | |\n|---|---|\n| TLRY Average Weekly Movement | 21.7% |\n| Pharmaceuticals Industry Average Movement | 10.1% |\n| Market Average Movement | 6.4% |\n| 10% most volatile stocks in US Market | 17.3% |\n| 10% least volatile stocks in US Market | 3.0% |\nStable Share Price: TLRY's share price has been volatile over the past 3 months compared to the US market.\nVolatility Over Time: TLRY's weekly volatility has increased from 14% to 22% over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| n/a | 2,842 | Irwin Simon | www.tilray.com |\nTilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products.\nTilray Brands, Inc. Fundamentals Summary\n| TLRY fundamental statistics | |\n|---|---|\n| Market cap | US$1.50b |\n| Earnings (TTM) | -US$2.19b |\n| Revenue (TTM) | US$821.31m |\nIs TLRY overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| TLRY income statement (TTM) | |\n|---|---|\n| Revenue | US$821.31m |\n| Cost of Revenue | US$579.13m |\n| Gross Profit | US$242.18m |\n| Other Expenses | US$2.43b |\n| Earnings | -US$2.19b |\nLast Reported Earnings\nMay 31, 2025\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | -1.99 |\n| Gross Margin | 29.49% |\n| Net Profit Margin | -266.25% |\n| Debt/Equity Ratio | 17.2% |\nHow did TLRY perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/28 10:16 |\n| End of Day Share Price | 2025/08/28 00:00 |\n| Earnings | 2025/05/31 |\n| Annual Earnings | 2025/05/31 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nTilray Brands, Inc. is covered by 28 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Aaron Grey | Alliance Global Partners |\n| Frederico Yokota Choucair Gomes | ATB Capital Markets |\n| Gaurav Jain | Barclays |"
    },
    {
      "url": "https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global?utm_medium=finance_user&utm_campaign=intro&utm_source=yahoo&blueprint=4024791",
      "text": "Results\n22\nThe best AI stocks today may lie beyond giants like Nvidia and Microsoft. Smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence present the next big opportunity and could fund your retirement.\n22 companies\nVuno\nMarket Cap: \u20a9274.3b\nVuno Inc. opera como empresa de desarrollo de soluciones de inteligencia artificial (IA) m\u00e9dica.\nA338220\n\u20a920,050.00\n7D\n-3.8%\n1Y\n-43.2%\nSES AI\nMarket Cap: US$409.6m\nSES AI Corporation desarrolla y produce tecnolog\u00edas de bater\u00edas recargables de iones de litio y metal de litio mejoradas con IA para veh\u00edculos el\u00e9ctricos, movilidad a\u00e9rea urbana, drones, rob\u00f3tica, sistemas de almacenamiento de energ\u00eda en bater\u00edas y otras aplicaciones.\nSES\nUS$1.11\n7D\n5.7%\n1Y\n4.7%\nAndes Technology\nMarket Cap: NT$14.3b\nAndes Technology Corporation ofrece soluciones para aplicaciones de sistemas integrados.\n6533\nNT$285.00\n7D\n8.4%\n1Y\n-22.6%\nInfomart\nMarket Cap: JP\u00a582.2b\nInfomart Corporation gestiona una plataforma de comercio electr\u00f3nico en l\u00ednea entre empresas (B2B) en Jap\u00f3n.\n2492\nJP\u00a5375.00\n7D\n0.3%\n1Y\n22.1%\nZero One Technology\nMarket Cap: NT$21.1b\nZero One Technology Co., Ltd. ofrece soluciones inform\u00e1ticas para empresas en Taiw\u00e1n.\n3029\nNT$124.00\n7D\n5.1%\n1Y\n34.1%\nSelvas AI\nMarket Cap: \u20a9348.8b\nSelvas AI Inc. opera como empresa de inteligencia artificial (IA) en Corea del Sur.\nA108860\n\u20a912,900.00\n7D\n2.0%\n1Y\n-10.1%\nEleco\nMarket Cap: UK\u00a3135.5m\nEleco plc ofrece software y servicios relacionados en el Reino Unido, Escandinavia, Alemania, el resto de Europa, Estados Unidos y a escala internacional.\nELCO\nUK\u00a31.63\n7D\n1.6%\n1Y\n19.9%\nFRONTEO\nMarket Cap: JP\u00a530.8b\nFRONTEO, Inc. ofrece soluciones y servicios de inteligencia artificial (IA) en Jap\u00f3n y a escala internacional.\n2158\nJP\u00a5820.00\n7D\n0.4%\n1Y\n12.3%\nRPMGlobal Holdings\nMarket Cap: AU$832.2m\nRPMGlobal Holdings Limited desarrolla y ofrece soluciones de software minero en Australia, Asia, Am\u00e9rica, \u00c1frica y Europa.\nRUL\nAU$3.77\n7D\n18.2%\n1Y\n52.0%\nBasler\nMarket Cap: \u20ac518.4m\nBasler Aktiengesellschaft se dedica al desarrollo, fabricaci\u00f3n y venta de c\u00e1maras digitales para usuarios profesionales en Alemania y a escala internacional.\nBSL\n\u20ac16.78\n7D\n6.3%\n1Y\n70.4%\nAgora\nMarket Cap: US$318.4m\nAgora, Inc. se dedica a la explotaci\u00f3n de una plataforma de compromiso en tiempo real como servicio en Estados Unidos, la Rep\u00fablica Popular China e internacionalmente.\nAPI\nUS$3.54\n7D\n0%\n1Y\n79.7%\nExaWizards\nMarket Cap: JP\u00a542.0b\nExaWizards Inc. desarrolla servicios basados en IA para la innovaci\u00f3n industrial y la resoluci\u00f3n de problemas sociales en Jap\u00f3n.\n4259\nJP\u00a5510.00\n7D\n1.4%\n1Y\n56.0%\nm-up holdings\nMarket Cap: JP\u00a587.2b\nm-up holdings, Inc. se dedica al desarrollo y distribuci\u00f3n de contenidos para m\u00f3viles y PC, y a negocios de comercio electr\u00f3nico en Jap\u00f3n.\n3661\nJP\u00a52,487.00\n7D\n-0.4%\n1Y\n95.5%\nCheetah Mobile\nMarket Cap: US$180.4m\nCheetah Mobile Inc., junto con sus filiales, presta servicios de Internet, inteligencia artificial (IA) y otros servicios en la Rep\u00fablica Popular China, Hong Kong, Jap\u00f3n y a escala internacional.\nCMCM\nUS$5.56\n7D\n-0.7%\n1Y\n57.1%\nEMRO\nMarket Cap: \u20a9517.3b\nEMRO., Incorporated. ofrece software de gesti\u00f3n de la cadena de suministro en Corea del Sur y a escala internacional.\nA058970\n\u20a941,900.00\n7D\n-0.8%\n1Y\n-17.4%\nData#3\nMarket Cap: AU$1.4b\nData#3 Limited ofrece soluciones y servicios de tecnolog\u00eda de la informaci\u00f3n (TI) en Australia.\nDTL\nAU$9.21\n7D\n15.1%\n1Y\n19.6%\nYidu Tech\nMarket Cap: HK$6.5b\nYidu Tech Inc, un holding de inversiones, ofrece soluciones sanitarias basadas en tecnolog\u00edas de big data e inteligencia artificial (IA) en la Rep\u00fablica Popular China, Brunei, Singapur y a escala internacional.\n2158\nHK$6.07\n7D\n-9.1%\n1Y\n83.4%\nCI&T\nMarket Cap: US$709.2m\nCI&T Inc., junto con sus filiales, presta servicios de estrategia, dise\u00f1o e ingenier\u00eda de software en todo el mundo.\nCINT\nUS$5.41\n7D\n6.9%\n1Y\n-20.2%\nPerfect\nMarket Cap: US$215.9m\nPerfect Corp, una empresa de software de inteligencia artificial como servicio, ofrece soluciones basadas en inteligencia artificial (IA) y realidad aumentada (RA) para los sectores de la belleza, la moda y el cuidado de la piel en todo el mundo.\nPERF\nUS$2.08\n7D\n9.5%\n1Y\n2.0%\nFixstars\nMarket Cap: JP\u00a559.6b\nFixstars Corporation opera como empresa de software en Jap\u00f3n y a escala internacional.\n3687\nJP\u00a51,907.00\n7D\n0.2%\n1Y\n19.2%\nCerillion\nMarket Cap: UK\u00a3416.0m\nCerillion Plc ofrece programas inform\u00e1ticos de facturaci\u00f3n, tarificaci\u00f3n y gesti\u00f3n de las relaciones con los clientes (CRM) al sector de las telecomunicaciones en el Reino Unido, Europa, Oriente Medio, Am\u00e9rica y Asia-Pac\u00edfico.\nCER\nUK\u00a314.10\n7D\n-2.8%\n1Y\n-27.1%\nESTsoft\nMarket Cap: \u20a9207.2b\nESTsoft Corp. se dedica al negocio del software en Corea del Sur.\nA047560\n\u20a920,050.00\n7D\n2.5%\n1Y\n29.2%"
    }
  ],
  "argos_summary": "Tilray Medical has launched three EU\u2011GMP certified medical cannabis strains in Germany, signalling a push into higher\u2011margin European markets. The move is part of Tilray\u2019s broader international expansion strategy, yet the company remains burdened by a $1.4\u202fbillion impairment and ongoing unprofitability in North America. While the German launch could boost revenue, regulatory uncertainty in key European markets and persistent U.S. legalization delays remain the biggest risks to Tilray\u2019s growth narrative.",
  "argos_id": "QUC5X5C5P"
}